# Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

> **NCT00256282** · PHASE2 · COMPLETED · sponsor: **John P. Fruehauf** · enrollment: 52 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Docetaxel
- **DRUG:** Sargramostim

## Key facts

- **NCT ID:** NCT00256282
- **Lead sponsor:** John P. Fruehauf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2018-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00256282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00256282, "Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00256282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*